Q3 EPS Estimate for Theravance Biopharma Boosted by Analyst

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Investment analysts at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Theravance Biopharma in a research report issued to clients and investors on Monday, October 21st. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of ($0.03) per share for the quarter, up from their prior forecast of ($0.09). The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.04) per share. Zacks Research also issued estimates for Theravance Biopharma's FY2025 earnings at ($0.01) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.04) EPS and FY2026 earnings at $0.55 EPS.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. The business had revenue of $14.26 million during the quarter, compared to analysts' expectations of $15.81 million. During the same period in the prior year, the firm posted ($0.28) EPS.

TBPH has been the topic of a number of other reports. StockNews.com cut shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a research note on Saturday, August 10th. Leerink Partners lowered Theravance Biopharma from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $15.00 to $10.00 in a report on Tuesday, August 6th. Leerink Partnrs lowered Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 6th. TD Cowen dropped their price target on Theravance Biopharma from $10.00 to $9.00 and set a "hold" rating on the stock in a research report on Tuesday, August 6th. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a report on Monday, September 16th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $13.75.

Theravance Biopharma Trading Down 1.9 %

Shares of NASDAQ:TBPH traded down $0.17 during midday trading on Wednesday, reaching $8.63. The company had a trading volume of 101,950 shares, compared to its average volume of 358,958. The stock has a market cap of $422.18 million, a P/E ratio of -9.38 and a beta of 0.25. The company's 50 day moving average price is $8.21 and its 200 day moving average price is $8.76. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $11.71.

Hedge Funds Weigh In On Theravance Biopharma

Hedge funds have recently bought and sold shares of the company. Kennedy Capital Management LLC increased its stake in Theravance Biopharma by 3.7% in the 1st quarter. Kennedy Capital Management LLC now owns 38,202 shares of the biopharmaceutical company's stock worth $343,000 after acquiring an additional 1,359 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Theravance Biopharma by 7.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company's stock worth $444,000 after purchasing an additional 3,532 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of Theravance Biopharma by 28.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company's stock worth $203,000 after purchasing an additional 4,990 shares during the last quarter. American Century Companies Inc. raised its stake in Theravance Biopharma by 11.7% in the second quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company's stock valued at $489,000 after purchasing an additional 6,026 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Theravance Biopharma by 16.6% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company's stock valued at $474,000 after purchasing an additional 7,509 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company's stock.

Insider Transactions at Theravance Biopharma

In related news, major shareholder Eli Samaha acquired 999,800 shares of the company's stock in a transaction that occurred on Wednesday, August 7th. The shares were acquired at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the acquisition, the insider now owns 9,511,150 shares of the company's stock, valued at approximately $74,186,970. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 6.90% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.